Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Federal Trade Commission
Covington
Dow
Farmers Insurance
McKesson
Chinese Patent Office
McKinsey

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAMIFLU

« Back to Dashboard

Clinical Trials for Tamiflu

Trial ID Title Status Sponsor Phase Summary
NCT00298233 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed University of Oxford Phase 2 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed Wellcome Trust Phase 2 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed World Health Organization Phase 2 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tamiflu

Condition Name

Condition Name for Tamiflu
Intervention Trials
Influenza 41
Healthy Volunteer 4
Healthy 4
Upper Respiratory Tract Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tamiflu
Intervention Trials
Influenza, Human 42
Infection 5
Respiratory Tract Infections 4
Virus Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tamiflu

Trials by Country

Trials by Country for Tamiflu
Location Trials
United States 275
Canada 38
Spain 16
Italy 15
Australia 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tamiflu
Location Trials
Texas 13
California 13
Florida 11
Pennsylvania 11
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tamiflu

Clinical Trial Phase

Clinical Trial Phase for Tamiflu
Clinical Trial Phase Trials
Phase 4 19
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tamiflu
Clinical Trial Phase Trials
Completed 36
Recruiting 7
Terminated 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tamiflu

Sponsor Name

Sponsor Name for Tamiflu
Sponsor Trials
Hoffmann-La Roche 24
National Institute of Allergy and Infectious Diseases (NIAID) 7
University of Oxford 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tamiflu
Sponsor Trials
Other 40
Industry 35
NIH 10
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Army
Federal Trade Commission
Express Scripts
Fuji
Healthtrust
Cerilliant
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.